ChemoSNiP
When a drug is administered to the body, the body responds to the drug itself. Not every patient responds to chemotherapy identically. ChemoSNiP, the blood test for chemotherapy, looks at how our body responds to a chemotherapeutic agent. This tells us whether our body removes the agent rapidly, thereby reducing its effectiveness or detoxing poorly; hence higher chances of toxicity. It allows a clinician to analyze how a patient’s body reacts to the specific drug.
ChemoSNiP is an innovative blood test done during chemotherapy that uses an advanced scientific technique called pharmacogenomics to analyze how a patient’s body will respond to a specific drug.
SNPs are variations in DNA sequence affecting the response to treatments, drugs, chemicals, etc. ChemoSNiP examines these variations to predict how your body will respond to various treatments.
Understanding how the body metabolizes drugs and how inherited gene variations influence drug response, the test provides insights into whether you’re likely to have a positive, negative, or no response to a specific drug.
When combined with data from chemosensitivity testing, ChemoSNiP helps narrow down treatment options to identify the most effective and least toxic therapeutic agent for each patient.
Reserve your 30-minute free consultation
With cutting-edge thermocyclers used, our test ChemoSNiP has the effectiveness to locate and analyze the SNPs.
The study of SNPs would allow for the selection of chemotherapeutic treatments that would benefit the patient with the least risk of adverse side effects.
The test provides insights and personalized analysis of drugs and treatments for each patient.
Oncotrail has undergone rigorous evaluation to ensure high sensitivity and specificity, making it an invaluable tool for diagnostic purposes.
Through high-precision techniques, the test is used to monitor the effectiveness of a particular cancer treatment. This would objectively provide information on how well the treatment is going.
The non-invasive tracking of the cancer status would notify a treating physician whether to adjust current management or stay the course. This would be important to know in almost real-time rather than to find out much later that a treatment doesn't apply to a particular person.
Whole peripheral blood sample
10 -15 ml of whole peripheral blood
6-8 days in the lab
30 days after sample collection
Applicable for all cancer types
To whom it is relevant: Whether the patient is currently undergoing cancer treatment or had cancer in the past, the test is a reliable follow-up and monitory tool to monitor the cancer or any potential signs of cancer recurrence.
A patient-centric revolution in cancer testing and monitoring. We are devoted to providing personalized tests designed with each patient’s unique genetic profile in mind.
©2024 All Rights Reserved. Designed by Bee High Media.
